Sidenote: Chew is also one of the few biopharma execs I've ever spoken to who voluntarily brought up the Institute for Clinical and Economic Review (ICER),
a tough drug pricing critic organization which insists on proven outcomes (and has consequently become a major biopharma gadfly), because the group actually validated the cost - effectiveness of Omada's tech.
Novartis (nvs) chief Joe Jiminez has been touting a
pricing model that incorporates
drugs» real - world outcomes for years, stressing the importance of placing patients before profits; Regeneron (regn) head honcho Len Schliefer had some
tough words for fellow panelists from Eli Lilly (lly) and Pfizer (pfe)(who argued that media reports about their own continued reliance on
price increases to drive revenues is misleading) during Forbes» event.